Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Daiwei (David) Zhang, PhD, is an Assistant Professor (tenure-track) in the Department of Biostatistics at the University of North Carolina at Chapel Hill School of Medicine, with a joint appointment in the Department of Genetics. His research focuses on developing AI frameworks for analyzing high-dimensional biomedical data, particularly in spatial omics, computational pathology, and medical imaging. Education: MS (Biostatistics) and PhD (Biostatistics and Scientific Computing) from the University of Michigan. Postdoctoral Training: University of Pennsylvania. Research interests include applying machine learning to address biomedical challenges such as tumor heterogeneity, immune interactions, and tissue architecture. His work spans computational methods for spatial transcriptomics, proteomics, and histology integration. Recent publications emphasize spatial multi-omics analysis of cancer ecosystems, tertiary lymphoid structures, and metabolic coordination. These studies leverage advanced machine learning algorithms and interdisciplinary approaches to advance precision medicine. No scientific awards are explicitly mentioned, but his work reflects significant contributions to biomedical AI research. Grants and advising details are not provided in the text.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.
Christopher M. Overall is a Full Professor at the University of British Columbia in the Faculty of Dentistry, Department of Oral Biological and Medical Sciences . He is also a Principal Scientist at the Centre for Blood Research and holds associate memberships in UBC's Biochemistry & Molecular Biology , Obstetrics and Gynecology , and Bioinformatics Graduate Program departments. As a Canada Research Chair Laureate , he pioneered the field of degradomics to study proteases in vivo. B.D.S., University of Adelaide Ph.D., University of Toronto Postdoctoral Fellowship, UBC (with Nobel Laureate Michael Smith) Dr. Overall’s research focuses on protease proteomics and systems biology , particularly degradomics to analyze protease substrates in diseases like COVID-19 and immunodeficiency . His work on matrix metalloproteinases has revealed new therapeutic strategies for inflammatory diseases and cancer . His 15 most recent articles (2015–2008) demonstrate expertise in TAILS proteomics , protein terminomics , and protease network analysis with applications in arthritis , antiviral immunity , and precision medicine . Scientific Awards 2022 Helmut Holzer Award 2018 Royal Society of Canada Fellow 2014 Tony Pawson Canadian Proteomics Award 2013 IADR Distinguished Scientist Award Dr. Overall has mentored 61 trainees , including 9 full professors with department chairs, and received the UBC John McNeill Mentorship Award (2023). He leads the HUPO Chromosome-centric Human Proteome Project and consults for Genentech and Novartis .
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Prof. Knut Drescher is an Associate Professor at the Biozentrum, University of Basel , leading a research group focused on bacterial biofilms , swarming , and microbial multicellularity . Previously, he served as a Professor of Biophysics and Max Planck Research Group Leader at Philipps-Universität Marburg (2015-2021) and conducted postdoctoral research at Princeton University. Research Interests: Physical and biological mechanisms of biofilm formation Cell-cell interactions in microbial communities Antibiotic resistance in biofilms Hydrodynamics of bacterial swarms Evolution of cooperation in multispecies biofilms Development of bioimaging software (BiofilmQ, BacStalk) Scientific Awards: 2023: SNSF Consolidator Grant 2019: Heinz Maier-Leibnitz Prize (DFG), VAAM Research Prize, IUPAP Young Scientist Prize 2016: ERC Starting Grant Advising & Grants: Advises PhD and Master's students in microbiology, biophysics, and bioinformatics Secured major grants from ERC , HFSP , and DFG
Houman Savoji is an Associate Professor in the Department of Pharmacology and Physiology at the Faculty of Medicine, University of Montreal. He is also a full-time researcher at the CHU Sainte-Justine Research Center and principal investigator in regenerative medicine, organs-on-chip, and bioprinting at TransMedTech Institute. Dr. Savoji received his PhD in Biomedical Engineering from the Institute of Biomedical Engineering at Polytechnique Montréal in 2016. He then completed a postdoctoral fellowship at the Institute of Biomaterials and Biomedical Engineering at the University of Toronto. His research expertise combines advanced manufacturing technologies (micro- and nano-fabrication, 3D bioprinting, microfluidics, cell electrospinning) with functional and composite materials for applications in tissue engineering, regenerative medicine, and organs-on-chip. His work focuses on the design, development, optimization, implementation, and characterization of innovative functional biomaterials using emerging engineering technologies, with particular emphasis on cardiac tissue engineering and biomimetic pulmonary heart valves for pediatric patients. Dr. Savoji has published extensively on biomaterials, tissue engineering, 3D bioprinting, and organ-on-chip technologies. His recent publications demonstrate expertise in viscoelastic characterization of soft tissues, engineering immune responses to biomaterials, ceramic engineering for biomedical applications, and advanced 3D bioprinting techniques for cardiac and vascular tissue engineering. 2017-2020, Postdoctoral Research Grant, CIHR 2017-2019, Postdoctoral Research Grant, FRQNT 2017-2018, Human Society of International Grant, Human Toxicity Assessment Project 2016, CR-CHUM Research Center Award 2015, Star Student-Researcher Award, FRQNT 2014-2015, Jane and Frank Warchol Fellowship, Society of Vacuum Coaters Foundation 2013, Institute of Textile Science Award 2012-2015, Excellence Doctoral Scholarship for Foreign Students, FRQNT Dr. Savoji has supervised Master's students including Ines Barrakad (2024) working on 'Advanced manufacturing technologies versus molding of corneal implants: 3D printing vs molding of a Keratoprosthesis' and Zineb Ajji (2023) researching 'Development of perfusable patches by 3D bioprinting for potential application in cardiac tissue regeneration.' He has secured numerous research grants from organizations including CIHR, NSERC, FRQNT, FRQS, MITACS, and others for projects related to 3D bioprinting of cardiac tissues, biomimetic heart valves, and other tissue engineering applications. The Savoji Laboratory, located within the Department of Pharmacology and Physiology and Institute of Biomedical Engineering of the Faculty of Medicine of the University of Montreal, the Research Center of the CHU Sainte-Justine (CHUSJ), and the TransMedTech Institute, focuses on multidisciplinary research involving 3D bioprinting using stem-cell derived human cardiac cells to fabricate functional cardiac tissues for transplantation and drug discovery applications.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Dr. Aaron Logan is a Clinical Associate Professor of Medicine at the University of California, San Francisco (UCSF). He specializes in the clinical management of acute leukemias, myelodysplastic syndromes, aplastic anemia, and hemophagocytic lymphohistiocytosis. Additionally, he directs a research laboratory focused on immune repertoire profiling following hematopoietic cell transplantation. MD and PhD in Molecular Microbiology and Immunology from Keck School of Medicine (2006) MPhil in History of Medicine from University of Cambridge (2005) Internal Medicine Residency and Hematology Fellowship at Stanford University Dr. Logan's research explores clonotypic diversity in B and T lymphocyte repertoires, utilizing techniques like TREC/KREC quantification, high-throughput sequencing, and mixed lymphocyte reactions. His work has significant applications in tracking immune responses post-transplantation and quantifying measurable residual disease in lymphoid cancers. Notable scientific contributions include advancements in CAR T-cell therapy and immune profiling for blood malignancies. His publications cover topics in B-cell ALL , AML , and measurable residual disease monitoring. 2020 - UCSF Hematology-Oncology Fellowship Teaching Award 2011 - ASH Abstract Award and Research Training Award 2003 - Keck School of Medicine Outstanding Teaching Award As director of the UCSF Hematologic Malignancies Tissue Bank, Dr. Logan provides deidentified patient samples to support collaborative research on blood cancers and post-transplantation immune dynamics.
Nonappa Nonappa is an Associate Professor (tenure track) in Nanochemistry at Tampere University's Faculty of Engineering and Natural Sciences since 2020. With a multidisciplinary background spanning organic chemistry, supramolecular systems, nanoparticle self-assembly, and advanced electron microscopy, he leads research at the intersection of materials science and biomedical applications. PhD in Organic Chemistry (IISc Bangalore, 2008) Docent in Soft Matter Microscopy (Aalto University, 2017) Executive MBA (Quantic School, 2020) Research focuses on bio-based optical materials using nanocellulose for sustainable photonics, breast cancer models via lab-on-a-chip systems, and precision nanomaterials through tailored self-assembly mechanisms. His team develops 3D extracellular matrices for cancer tissue culture and plasmonic nanodevices for photonic applications. Recent publications highlight gold/silver nanocluster assemblies (43+ citations in 2021-2025), electron tomography for structural analysis, and metastasis modeling systems. Key awards include Italy's Abilitazione Scientifica Nazionale (2018) and Aalto University's Docent title (2017).
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Omer Bayraktar is a Group Leader at the Wellcome Sanger Institute , leading research in the Cellular Genomics Programme. His work focuses on decoding human brain cellular diversity using spatial transcriptomics , imaging , and functional screening to study neural complexity in health and disease. Bayraktar's educational background includes a PhD from HHMI under Chris Doe, investigating neural diversity development in Drosophila , followed by postdoctoral work at University of California, San Francisco and University of Cambridge as a Life Sciences Research Foundation Fellow. He developed a spatial transcriptomic pipeline during his postdoc to analyze astrocyte heterogeneity in the cerebral cortex. His research explores neural cell type mapping , glial-neuronal interactions , and cellular pathways in neurodevelopmental disorders . Recent publications emphasize 3D tissue mapping , multi-omic integration , and computational tools like Cell2fate and WebAtlas. His work bridges neurogenetics and computational biology to advance understanding of human tissue ecosystems. Bayraktar's lab collaborates with the Human Cell Atlas initiative and develops technologies such as automated histology pipelines and highly-multiplexed smFISH for molecular cell typing. His team also investigates glia-based therapies and astrocyte functional heterogeneity in neurodevelopmental contexts. Key scientific contributions include: Discovering astrocyte layer patterns independent of neuronal laminae Developing cell2location for spatial cell mapping Characterizing Drosophila neural stem cell models with human relevance Notable awards include the Life Sciences Research Foundation Fellowship during his postdoctoral training. His current group includes a PhD student , Senior Data Scientists , and Bioinformaticians .
Marco Fritzsche is a Professor of Biophysical Immunology at the University of Oxford. He serves as the Scientific Director of the Oxford-ZEISS Centre of Excellence and leads the Biophysical Immunology Laboratory (www.bpi-oxford.com), which operates at the intersection of biophysics and immunology. BSc in Mathematics (2003–2006), University of Saarbrücken BSc in Physics (2003–2006), University of Saarbrücken MSc in Theoretical Physics (2006–2008), University of Saarbrücken PhD in Experimental Physics and Biology (2008–2012), University College London His research focuses on biophysical and mechanobiological mechanisms governing immune responses in health and disease. The BPI Laboratory develops advanced microscopy technologies to study these processes, integrating theoretical physics with experimental immunology. Recent publications highlight his work in quantitative imaging of biomolecular organization , traction force microscopy for immune cell dynamics, and trans-synaptic vesicle analysis in T-cell interactions. His studies bridge disciplines like biophysics, immunology, and cell mechanics. Rosalind Franklin Kennedy Trust Research Fellow The BPI Laboratory collaborates with institutions such as the Howard Hughes Medical Institute Janelia Farm and the Rosalind Franklin Institute . His roles include leadership in the Oxford-ZEISS Centre of Excellence and contributions to cutting-edge immunology research.
